Sign Out
Pregnancy: There are no data from the use of letermovir in pregnant women. Studies in animals have shown reproductive toxicity (see Pharmacology: Toxicology: Preclinical safety data under Actions).
PREVYMIS is not recommended during pregnancy and in women of childbearing potential not using contraception.
Breast-feeding: It is unknown whether letermovir is excreted in human milk.
Available pharmacodynamic/toxicological data in animals have shown excretion of letermovir in milk (see Pharmacology: Toxicology: Preclinical safety data under Actions).
A risk to the newborns/infants cannot be excluded.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from PREVYMIS therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Fertility: There were no effects on female fertility in rats. Irreversible testicular toxicity and impairment of fertility was observed in male rats, but not in male mice or male monkeys.
Continue with Google